Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor

Demographic, Clinical, Histological and Molecular Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohort, an Observational Cohort Study: Lung Cancer ID Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06076005

Acronym

LUNG-CANCER

Enrollment

1000

Registered

2023-10-10

Start date

2023-11-01

Completion date

2026-08-31

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer Stage IV

Brief summary

The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.

Interventions

OTHERAdvanced lung cancer patients' group

Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age \>18 years * Suspicion of lung cancer based on imaging (CT and/or PET/CT) * Indication to a biopsy for diagnosis, staging and/or molecular profiling

Exclusion criteria

* Inability or unwillingness to provide a written informed consent * ECOG performance status (\>3) which makes a tissue diagnosis unfeasible * ASA 4 status * TNM Stage I-III

Design outcomes

Primary

Measure	Time frame	Description
Distribution of histologic subtypes	24 months	The investigators will assess the prevalence of histologic subtypes in patients with advanced lung cancer

Secondary

Measure	Time frame	Description
Distribution of histologic subtypes according to clinical and radiological characteristics	24 months	The investigators will assess the prevalence of different histologic subtypes according to clinical and imaging characteristics
Molecular profiling	24 months	Prevalence of individual molecular markers in patients with advanced non-squamous non-small cell lung cancer histology
Time to diagnosis	24 months	Time lag between onset of symptoms (if any) and invasive testing

Countries

Italy

Contacts

Primary ContactRocco Trisolini, MD

rocco.trisolini@policlinicogemelli.it0630154163

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026